This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Exner, M. Articles by Schillinger, M. Search for Related Content PubMed PubMed Citation Articles by Exner, M. Articles by Schillinger, M.

Myeloperoxidase Predicts Progression of Carotid Stenosis in States of Low High-Density Lipoprotein Cholesterol

Markus Exner, MD^_*, Erich Minar, MD, Wolfgang Mlekusch, MD, Schila Sabeti, MD, Jasmin Amighi, MD, Wolfgang Lalouschek, MD, Gerald Maurer, MD, Christian Bieglmayer, PhD^_*, Heidi Kieweg^_*, Oswald Wagner, MD^_* and Martin Schillinger, MD^,_*

^_* Medical and Chemical Laboratory Diagnostics
Angiology
Neurology
Cardiology, Medical University Vienna, Vienna, Austria

View larger version (23K): [in a new window]   Figure 1 Frequency of patients with progression of carotid artery disease, measured by duplex ultrasound, according to myeloperoxidase (MPO, in quartiles) and high-density lipoprotein (HDL, in quartiles) levels.

View larger version (22K): [in a new window]   Figure 2 Forrest plot describing the risk for progression of carotid atherosclerosis by duplex ultrasound from baseline to follow-up after median 7.5 months (interquartile range 6 to 9 months) calculated by multivariable logistic regression analysis. Models adjusted for age, gender, body mass index, family history of atherosclerotic disease, hypertension, current smoking, glycated hemoglobin A1, low-density lipoprotein cholesterol, serum creatinine, history of myocardial infarction, history of stroke, stain therapy, and baseline degree of carotid atherosclerosis. CI = confidence interval; HDL = high-density lipoprotein; MPO = myeloperoxidase.